Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 59, Issue 9, 2010, Pages 1294-1299

  Konya, Hiroyuki ^a   Hasegawa, Yoshikazu ^a   Hamaguchi, Tomoya ^a   Satani, Kahori ^a   Umehara, Akiko ^a   Katsuno, Tomoyuki ^a   Ishikawa, Tetsuya ^a   Miuchi, Masayuki ^a   Kohri, Kousuke ^a   Suehiro, Akira ^a   Kakishita, Eizo ^a   Miyagawa, Jun Ichiro ^a   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; FIBRINOGEN; GLIBENCLAMIDE; GLICLAZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOREACTIVE INSULIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEROTONIN; THROMBIN ANTITHROMBIN COMPLEX; TRIACYLGLYCEROL; 3' (O) 2' AZIDO 2' DEOXYURIDINE 5' DIPHOSPHATE; 3'-(O)-2'-AZIDO-2'-DEOXYURIDINE 5'-DIPHOSPHATE; ALPHA 2 ANTIPLASMIN; ANTIDIABETIC AGENT; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; AZIDE; DEOXYURIDINE PHOSPHATE; GLYCOSYLATED HEMOGLOBIN; INSULIN; PEPTIDE HYDROLASE; PLASMIN; PLASMIN PLASMIN INHIBITOR COMPLEX; PLASMIN-PLASMIN INHIBITOR COMPLEX;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC ANGIOPATHY; DRUG DOSE TITRATION; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; LIGHT SCATTERING; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; VASCULAR DISEASE; AGED; BLOOD; DRUG EFFECT; MIDDLE AGED;

AGED; ALPHA-2-ANTIPLASMIN; ANTITHROMBIN III; AZIDES; BLOOD GLUCOSE; BODY MASS INDEX; DEOXYURACIL NUCLEOTIDES; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOLYSIN; GLICLAZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION;

EID: 77956635379     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.12.004     Document Type: Article

References (20)

1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
3. Fukuda K., Ozaki Y., Satoh K., Kume S., Tawata M., and Onaya T. Phosphorylation of myosin light chain in resting platelets from NIDDM patients is enhanced: correlation with spontaneous aggregation Diabetes 46 1997 488 493
4. Sakamoto T., Ogawa H., Kawano H., Hirai N., Miyamoto S., and Takazoe K. Rapid change of platelet aggregability in acute hyperglycemia. Detection by a novel laser-light scattering method Thromb Haemost 83 2000 475 479
5. Malyszko J., Urano T., Knofler R., Taminato A., Yoshimi T., and Takada Y. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes Thromb Res 75 1994 569 576
6. Satoh K., Ozaki Y., Qi R., Yang L., Asazuma N., and Yatomi Y. Factors that affect the size of platelet aggregates in epinephrine-induced activation: a study using the particle counting method based upon light scattering Thromb Res 81 1996 515 523
7. Juhan-Vague I., Alessi M.C., and Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus Ann Med 28 1996 371 380
8. Pagano P.J., Griswold M.C., Ravel D., and Cohen R.A. Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits Diabetologia 41 1998 9 15
9. Jennings P.E., Scott N.A., Saniabadi A.R., and Belch J.J. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment Metabolism 41 1992 36 39
10. Fu Z.Z., Yan T., Chen Y.J., and Sang J.Q. Thromboxane/prostacyclin balance in type II diabetes: gliclazide effects Metabolism 41 Suppl 1 1992 33 35
11. Gram J., Kold A., and Jespersen J. Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolubutamide) to a second generation sulfonylurea (gliclazide) J Intern Med 225 1989 241 247
12. Renier G., Desfaits A.C., and Serri O. Effect of gliclazide on monocyte-endothelium interactions in diabetes J Diabetes Complications 14 2000 215 223
13. Suehiro A., Yoshimoto H., Higasa S., and Kakishita E. Platelet aggregating activity of plasma in patients with thrombotic thrombocytopenic purpura evaluated by a particle counting method using light scattering Int. J. Hematol 70 1999 40 46
14. Ono Y., Aoki S., Ohnishi K., Yasuda T., Kawano K., and Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications Diabetes Res. Clin. Pract 41 1998 131 137
15. Hasegawa Y., Suehiro A., Higasa S., Namba M., and Kakishita E. Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus Thromb Res 107 2002 319 323
16. Siluk D., Kaliszan R., Haber P., Petrusewicz J., Brzozowski Z., and Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas Diabetologia 45 2002 1034 1037
17. Cefalu W.T., Schneider D.J., Carlson H.E., Migdal P., Gan Lim L., and Izon M.P. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects Diabetes Care 25 2002 2123 2128
18. Katakami N., Yamasaki Y., Hayaishi-Okano R., Ohtoshi K., Kaneto H., and Matsuhisa M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes Diabetologia 47 2004 1906 1913
19. Johnsen S.P., Monster T.B., Olsen M.L., Thisted H., McLaughlin J.K., and Sørensen H.T. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs Am J Ther 13 2006 134 140
20. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572